Literature DB >> 21749220

HOXA4 induces expansion of hematopoietic stem cells in vitro and confers enhancement of pro-B-cells in vivo.

Marilaine Fournier1, Charles-Étienne Lebert-Ghali, Gorazd Krosl, Janet J Bijl.   

Abstract

Members of the homeobox (Hox) gene family are known to mediate expansion of hematopoietic stem cells (HSCs) and progenitors. The absence of oncogenic properties promoted HOXB4 as prime candidate in the quest to expand HSCs for clinical purposes. Despite its potential to expand HSCs, studies with mutant mice showed that Hoxb4 is not essential for HSC generation and function under physiological conditions. Expression studies and the existence of functional redundancy in particular between paralog Hox genes suggest that HOXA4 might have potent properties to expand HSCs. Here we measured the ability of HOXA4 to promote ex vivo expansion of HSCs and progenitors using retrovirus-mediated overexpression. Our results provide evidence that HOXA4-transduced HSCs and primitive progenitors expand in culture conditions and demonstrate that the potential of expanded HOXA4 HSCs to give rise to mature myeloid and lymphoid progeny in normal proportions remained intact. Interestingly, constitutive overexpression of HOXA4 resulted in an unbalanced expansion of lymphoid/myeloid progenitors in bone marrow chimeras favorable to B-cell progenitors responsive to interleukin-7. This expansion was specific for these progenitors and not for the more primitive Whitlock-Witte-initiating cells. These data indicate that early stages of B-cell development associated with proliferation are in particular sensitive to HOXA4. Thus, this study supports the potential use of HOXA4 to expand both HSCs and B-cell progenitor populations for therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21749220     DOI: 10.1089/scd.2011.0259

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  9 in total

1.  HOXA4 provides stronger engraftment potential to short-term repopulating cells than HOXB4.

Authors:  Marilaine Fournier; Charles-Étienne Lebert-Ghali; Janetta J Bijl
Journal:  Stem Cells Dev       Date:  2015-08-12       Impact factor: 3.272

Review 2.  Novel chemical attempts at ex vivo hematopoietic stem cell expansion.

Authors:  Yu Zhang; Yingdai Gao
Journal:  Int J Hematol       Date:  2016-02-24       Impact factor: 2.490

3.  Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.

Authors:  Marjanu Hikmah Elias; Husin Azlan; Sarina Sulong; Abdul Aziz Baba; Ravindran Ankathil
Journal:  Cancer Rep (Hoboken)       Date:  2018-07-27

4.  Unveiling combinatorial regulation through the combination of ChIP information and in silico cis-regulatory module detection.

Authors:  Hong Sun; Tias Guns; Ana Carolina Fierro; Lieven Thorrez; Siegfried Nijssen; Kathleen Marchal
Journal:  Nucleic Acids Res       Date:  2012-03-15       Impact factor: 16.971

5.  Promoter methylation and expression levels of selected hematopoietic genes in pediatric B-cell acute lymphoblastic leukemia.

Authors:  Ewa Musialik; Mateusz Bujko; Paulina Kober; Agnieszka Wypych; Karolina Gawle-Krawczyk; Michal Matysiak; Janusz Aleksander Siedlecki
Journal:  Blood Res       Date:  2015-03-24

Review 6.  Increasing hematopoietic stem cell yield to develop mice with human immune systems.

Authors:  Juan-Carlos Biancotti; Terrence Town
Journal:  Biomed Res Int       Date:  2013-02-14       Impact factor: 3.411

7.  HOXA4 gene promoter hypermethylation as an epigenetic mechanism mediating resistance to imatinib mesylate in chronic myeloid leukemia patients.

Authors:  Marjanu Hikmah Elias; Abdul Aziz Baba; Azlan Husin; Sarina Sulong; Rosline Hassan; Goh Ai Sim; S Fadilah Abdul Wahid; Ravindran Ankathil
Journal:  Biomed Res Int       Date:  2012-12-26       Impact factor: 3.411

8.  Evolving DNA methylation and gene expression markers of B-cell chronic lymphocytic leukemia are present in pre-diagnostic blood samples more than 10 years prior to diagnosis.

Authors:  Panagiotis Georgiadis; Irene Liampa; Dennie G Hebels; Julian Krauskopf; Aristotelis Chatziioannou; Ioannis Valavanis; Theo M C M de Kok; Jos C S Kleinjans; Ingvar A Bergdahl; Beatrice Melin; Florentin Spaeth; Domenico Palli; R C H Vermeulen; J Vlaanderen; Marc Chadeau-Hyam; Paolo Vineis; Soterios A Kyrtopoulos
Journal:  BMC Genomics       Date:  2017-09-13       Impact factor: 3.969

9.  The balance between the intronic miR-342 and its host gene Evl determines hematopoietic cell fate decision.

Authors:  Friederike Herbst; Tonio J L Lang; Elias S P Eckert; Peer Wünsche; Alexander A Wurm; Tim Kindinger; Karin Laaber; Shayda Hemmati; Agnes Hotz-Wagenblatt; Oksana Zavidij; Anna Paruzynski; Junyan Lu; Christof von Kalle; Thorsten Zenz; Christoph Klein; Manfred Schmidt; Claudia R Ball; Hanno Glimm
Journal:  Leukemia       Date:  2021-05-21       Impact factor: 11.528

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.